Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22414766 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed 4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients
Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127 middle dose +SOC;   Drug: BI 207127 high dose+SOC;   Drug: Placebo + SOC;   Drug: BI 207127 low dose + SOC

Indicates status has not been verified in more than two years